INSUBCONTINENT EXCLUSIVE:
Mumbai: Positive commentary by leading brokerages Credit Suisse and Nomura helped shares of pharma major Lupin end up nearly 3 per cent at
The brokerage said its concerns on specialty drug Solosec have played out and it is upgrading the stock as it is now ignoring the sharp
net debt in past four years due to weak acquisitions (Gavis, Solosec) and low FCF
challenging with limited scope for new product introductions (consequence of patent regime and tougher regulatory standards) and
is scope for significant frontend synergies across markets," said Nomura.
